<!DOCTYPE html>
<html >

<head>

  <meta charset="UTF-8">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <title>Summary of Conferences 2016</title>
  <meta name="description" content="Conferences mainly regarding clinical pharmacology, pharmacometrics and medicine will be summarized here.">
  <meta name="generator" content="bookdown 0.3.11 and GitBook 2.6.7">

  <meta property="og:title" content="Summary of Conferences 2016" />
  <meta property="og:type" content="book" />
  <meta property="og:url" content="http://shanmdphd.github.io/Conferences/" />
  <meta property="og:image" content="http://shanmdphd.github.io/Conferences/images/cover.png" />
  <meta property="og:description" content="Conferences mainly regarding clinical pharmacology, pharmacometrics and medicine will be summarized here." />
  <meta name="github-repo" content="shanmdphd/shanmdphd.github.io" />

  <meta name="twitter:card" content="summary" />
  <meta name="twitter:title" content="Summary of Conferences 2016" />
  
  <meta name="twitter:description" content="Conferences mainly regarding clinical pharmacology, pharmacometrics and medicine will be summarized here." />
  <meta name="twitter:image" content="http://shanmdphd.github.io/Conferences/images/cover.png" />

<meta name="author" content="Sungpil Han, M.D./Ph.D.">


<meta name="date" content="2017-03-21">

  <meta name="viewport" content="width=device-width, initial-scale=1">
  <meta name="apple-mobile-web-app-capable" content="yes">
  <meta name="apple-mobile-web-app-status-bar-style" content="black">
  
  
<link rel="prev" href="toxicology-2016.html">
<link rel="next" href="the-2nd-a3-pharmacometrics-symposium.html">
<script src="libs/jquery/jquery.min.js"></script>
<link href="libs/gitbook/css/style.css" rel="stylesheet" />
<link href="libs/gitbook/css/plugin-bookdown.css" rel="stylesheet" />
<link href="libs/gitbook/css/plugin-highlight.css" rel="stylesheet" />
<link href="libs/gitbook/css/plugin-search.css" rel="stylesheet" />
<link href="libs/gitbook/css/plugin-fontsettings.css" rel="stylesheet" />










<link rel="stylesheet" href="css/style.css" type="text/css" />
</head>

<body>



  <div class="book without-animation with-summary font-size-2 font-family-1" data-basepath=".">

    <div class="book-summary">
      <nav role="navigation">

<ul class="summary">
<li><a href="./">Conferences</a></li>

<li class="divider"></li>
<li class="chapter" data-level="1" data-path="index.html"><a href="index.html"><i class="fa fa-check"></i><b>1</b> Introduction</a></li>
<li class="chapter" data-level="2" data-path="section-2.html"><a href="section-2.html"><i class="fa fa-check"></i><b>2</b> 심장내과</a></li>
<li class="chapter" data-level="3" data-path="-3.html"><a href="-3.html"><i class="fa fa-check"></i><b>3</b> 심장내과 3부</a></li>
<li class="chapter" data-level="4" data-path="cancer-immunotherapy.html"><a href="cancer-immunotherapy.html"><i class="fa fa-check"></i><b>4</b> Cancer immunotherapy</a></li>
<li class="chapter" data-level="5" data-path="bioimaging-2016-04-29.html"><a href="bioimaging-2016-04-29.html"><i class="fa fa-check"></i><b>5</b> Bioimaging 2016-04-29</a></li>
<li class="chapter" data-level="6" data-path="-fda-.html"><a href="-fda-.html"><i class="fa fa-check"></i><b>6</b> 신약개발을 위한 FDA의 바이오이미징 표준화 프로그램 |</a><ul>
<li class="chapter" data-level="6.1" data-path="-fda-.html"><a href="-fda-.html#-center-for-bioimaging-of-new-drug-development-amc"><i class="fa fa-check"></i><b>6.1</b> 김정곤 Center for Bioimaging of New Drug Development AMC</a></li>
</ul></li>
<li class="chapter" data-level="7" data-path="kscpt.html"><a href="kscpt.html"><i class="fa fa-check"></i><b>7</b> 2016 KSCPT</a><ul>
<li class="chapter" data-level="7.1" data-path="kscpt.html"><a href="kscpt.html#first-session"><i class="fa fa-check"></i><b>7.1</b> First Session</a><ul>
<li class="chapter" data-level="7.1.1" data-path="kscpt.html"><a href="kscpt.html#precision-medicine-a-clinical-pharmacological-perspective"><i class="fa fa-check"></i><b>7.1.1</b> 13:20~14:00 Precision Medicine: A Clinical Pharmacological Perspective</a></li>
<li class="chapter" data-level="7.1.2" data-path="kscpt.html"><a href="kscpt.html#the-role-of-pharmacogenomics-in-drug-development-regulatory-review-and-clinical-practice"><i class="fa fa-check"></i><b>7.1.2</b> 14:00~14:30 The role of pharmacogenomics in drug development, regulatory review and clinical practice</a></li>
<li class="chapter" data-level="7.1.3" data-path="kscpt.html"><a href="kscpt.html#the-liver-gut-microbiota-axis-modulates-inter-individual-variability-in-xenobiotic-disposition-and-toxicology"><i class="fa fa-check"></i><b>7.1.3</b> 14:30~15:00 The Liver-Gut Microbiota Axis Modulates Inter-Individual Variability in Xenobiotic Disposition and Toxicology</a></li>
</ul></li>
<li class="chapter" data-level="7.2" data-path="kscpt.html"><a href="kscpt.html#second-session"><i class="fa fa-check"></i><b>7.2</b> Second Session</a><ul>
<li class="chapter" data-level="7.2.1" data-path="kscpt.html"><a href="kscpt.html#the-role-of-stem-cells-in-discovery-and-validation-of-pharmacogenomic-markers"><i class="fa fa-check"></i><b>7.2.1</b> 15:20~15:50 The role of stem cells in discovery and validation of pharmacogenomic markers</a></li>
<li class="chapter" data-level="7.2.2" data-path="kscpt.html"><a href="kscpt.html#pharmacogenomics-and-epigenomics"><i class="fa fa-check"></i><b>7.2.2</b> 15:50~16:20 Pharmacogenomics and Epigenomics</a></li>
<li class="chapter" data-level="7.2.3" data-path="kscpt.html"><a href="kscpt.html#emerging-roles-of-human-cyp1b1-in-cancer-growth-and-metastasis"><i class="fa fa-check"></i><b>7.2.3</b> 16:20~16:50 Emerging roles of human CYP1B1 in cancer growth and metastasis</a></li>
<li class="chapter" data-level="7.2.4" data-path="kscpt.html"><a href="kscpt.html#omics-for-precision-medicine-clinical-implementation-in-oncology"><i class="fa fa-check"></i><b>7.2.4</b> 16:50~17:20 omics for precision Medicine : Clinical Implementation in oncology</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="8" data-path="translation-and-convergence-for-future-medicine.html"><a href="translation-and-convergence-for-future-medicine.html"><i class="fa fa-check"></i><b>8</b> “Translation and Convergence for Future Medicine”</a><ul>
<li class="chapter" data-level="8.1" data-path="translation-and-convergence-for-future-medicine.html"><a href="translation-and-convergence-for-future-medicine.html#plenary-session-ii--rd-"><i class="fa fa-check"></i><b>8.1</b> Plenary Session II “의료기술및 R&amp;D 변화의최신동향”</a><ul>
<li class="chapter" data-level="8.1.1" data-path="translation-and-convergence-for-future-medicine.html"><a href="translation-and-convergence-for-future-medicine.html#lecture-1--------"><i class="fa fa-check"></i><b>8.1.1</b> 13:30 ~ 14:15 Lecture 1 :의료분야에서의 빅데이터 :임상연구 및 진료를 위한 애널리틱스의 활용</a></li>
<li class="chapter" data-level="8.1.2" data-path="translation-and-convergence-for-future-medicine.html"><a href="translation-and-convergence-for-future-medicine.html#lecture-2----"><i class="fa fa-check"></i><b>8.1.2</b> 14:15 ~ 15:00 Lecture 2 :합성 항체에서 합성 단백질로</a></li>
</ul></li>
<li class="chapter" data-level="8.2" data-path="translation-and-convergence-for-future-medicine.html"><a href="translation-and-convergence-for-future-medicine.html#parallel-session-i--chairperson--"><i class="fa fa-check"></i><b>8.2</b> Parallel Session I “의료분야에서의빅데이터” Chairperson :김태원(서울아산병원임상의학연구소장) [대강당]</a><ul>
<li class="chapter" data-level="8.2.1" data-path="translation-and-convergence-for-future-medicine.html"><a href="translation-and-convergence-for-future-medicine.html#lecture-1------alexander-turchin-harvard-university-brigham-and-womens-hospital-usa"><i class="fa fa-check"></i><b>8.2.1</b> Lecture 1 :전자의무기록에 기반한 임상 빅데이터 연구 Alexander Turchin (Harvard University, Brigham and Women’s Hospital, USA)</a></li>
<li class="chapter" data-level="8.2.2" data-path="translation-and-convergence-for-future-medicine.html"><a href="translation-and-convergence-for-future-medicine.html#lecture-2----tom-lawry-microsoft-corp.-usa"><i class="fa fa-check"></i><b>8.2.2</b> Lecture 2 : 의료분야에서의 빅데이터 분석 Tom Lawry (Microsoft Corp., USA)</a></li>
<li class="chapter" data-level="8.2.3" data-path="translation-and-convergence-for-future-medicine.html"><a href="translation-and-convergence-for-future-medicine.html#lecture-3-------"><i class="fa fa-check"></i><b>8.2.3</b> Lecture 3 :생물기작 기반 암 오믹스 데이터 분석 기법</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="9" data-path="acrep.html"><a href="acrep.html"><i class="fa fa-check"></i><b>9</b> ACREP</a><ul>
<li class="chapter" data-level="9.1" data-path="acrep.html"><a href="acrep.html#observational-study"><i class="fa fa-check"></i><b>9.1</b> Observational Study</a><ul>
<li class="chapter" data-level="9.1.1" data-path="acrep.html"><a href="acrep.html#contents"><i class="fa fa-check"></i><b>9.1.1</b> Contents</a></li>
</ul></li>
<li class="chapter" data-level="9.2" data-path="acrep.html"><a href="acrep.html#observational-study-pitfall-----"><i class="fa fa-check"></i><b>9.2</b> Observational Study의 Pitfall 및 이를 극복하기 위한 방법</a><ul>
<li class="chapter" data-level="9.2.1" data-path="acrep.html"><a href="acrep.html#experimental-study-yes"><i class="fa fa-check"></i><b>9.2.1</b> Experimental study? Yes</a></li>
<li class="chapter" data-level="9.2.2" data-path="acrep.html"><a href="acrep.html#experimental-study-no"><i class="fa fa-check"></i><b>9.2.2</b> Experimental study? No</a></li>
<li class="chapter" data-level="9.2.3" data-path="acrep.html"><a href="acrep.html#contents-1"><i class="fa fa-check"></i><b>9.2.3</b> Contents</a></li>
<li class="chapter" data-level="9.2.4" data-path="acrep.html"><a href="acrep.html#conclusion"><i class="fa fa-check"></i><b>9.2.4</b> Conclusion</a></li>
</ul></li>
<li class="chapter" data-level="9.3" data-path="acrep.html"><a href="acrep.html#diagnostic-test-biomarker-study"><i class="fa fa-check"></i><b>9.3</b> Diagnostic test &amp; Biomarker Study</a><ul>
<li class="chapter" data-level="9.3.1" data-path="acrep.html"><a href="acrep.html#contents---diagnostic-test"><i class="fa fa-check"></i><b>9.3.1</b> Contents - Diagnostic test</a></li>
<li class="chapter" data-level="9.3.2" data-path="acrep.html"><a href="acrep.html#contents---biomarker"><i class="fa fa-check"></i><b>9.3.2</b> Contents - Biomarker</a></li>
</ul></li>
<li class="chapter" data-level="9.4" data-path="acrep.html"><a href="acrep.html#----"><i class="fa fa-check"></i><b>9.4</b> 2차 자료원을 이용한 역학 연구군</a></li>
<li class="chapter" data-level="9.5" data-path="acrep.html"><a href="acrep.html#----clinical-prediction-model-individual-riskoutcome-probability--"><i class="fa fa-check"></i><b>9.5</b> 대규모 이차 자료원을 이용한 clinical prediction model : individual risk/outcome probability 예측 분석법</a></li>
<li class="chapter" data-level="9.6" data-path="acrep.html"><a href="acrep.html#web-r.org"><i class="fa fa-check"></i><b>9.6</b> Web-r.org</a><ul>
<li class="chapter" data-level="9.6.1" data-path="acrep.html"><a href="acrep.html#contents-2"><i class="fa fa-check"></i><b>9.6.1</b> Contents</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="10" data-path="prism-2016.html"><a href="prism-2016.html"><i class="fa fa-check"></i><b>10</b> Prism 2016</a><ul>
<li class="chapter" data-level="10.1" data-path="prism-2016.html"><a href="prism-2016.html#morning-session"><i class="fa fa-check"></i><b>10.1</b> Morning Session</a><ul>
<li class="chapter" data-level="10.1.1" data-path="prism-2016.html"><a href="prism-2016.html#lim-covariate-model"><i class="fa fa-check"></i><b>10.1.1</b> Lim Covariate model</a></li>
<li class="chapter" data-level="10.1.2" data-path="prism-2016.html"><a href="prism-2016.html#fda---lee"><i class="fa fa-check"></i><b>10.1.2</b> FDA - Lee</a></li>
<li class="chapter" data-level="10.1.3" data-path="prism-2016.html"><a href="prism-2016.html#pfizer"><i class="fa fa-check"></i><b>10.1.3</b> Pfizer</a></li>
</ul></li>
<li class="chapter" data-level="10.2" data-path="prism-2016.html"><a href="prism-2016.html#afternoon-session"><i class="fa fa-check"></i><b>10.2</b> Afternoon Session</a><ul>
<li class="chapter" data-level="10.2.1" data-path="prism-2016.html"><a href="prism-2016.html#kim"><i class="fa fa-check"></i><b>10.2.1</b> Kim</a></li>
<li class="chapter" data-level="10.2.2" data-path="prism-2016.html"><a href="prism-2016.html#strategic-application-of-pm-in-global-drug-development-experience-from-hanmi"><i class="fa fa-check"></i><b>10.2.2</b> Strategic application of PM in global drug development: Experience from Hanmi</a></li>
<li class="chapter" data-level="10.2.3" data-path="prism-2016.html"><a href="prism-2016.html#mbdd"><i class="fa fa-check"></i><b>10.2.3</b> MBDD</a></li>
<li class="chapter" data-level="10.2.4" data-path="prism-2016.html"><a href="prism-2016.html#pharmacometric-information-in-drug-label"><i class="fa fa-check"></i><b>10.2.4</b> Pharmacometric information in drug label</a></li>
<li class="chapter" data-level="10.2.5" data-path="prism-2016.html"><a href="prism-2016.html#pharmacometrics-in-dose-optimization"><i class="fa fa-check"></i><b>10.2.5</b> Pharmacometrics in Dose Optimization</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="11" data-path="MFDS.html"><a href="MFDS.html"><i class="fa fa-check"></i><b>11</b> MFDS-Asan Joint Symposium on Rare Diseases 2016</a><ul>
<li class="chapter" data-level="11.1" data-path="MFDS.html"><a href="MFDS.html#session-1-rare-diseases-in-korea-status-research-experiences"><i class="fa fa-check"></i><b>11.1</b> Session 1 Rare diseases in Korea : Status &amp; Research experiences</a><ul>
<li class="chapter" data-level="11.1.1" data-path="MFDS.html"><a href="MFDS.html#national-support-for-rare-disease-current-status-and-future-prospects"><i class="fa fa-check"></i><b>11.1.1</b> National support for rare disease : Current status and future prospects</a></li>
<li class="chapter" data-level="11.1.2" data-path="MFDS.html"><a href="MFDS.html#translational-research-for-drug-development-historical-perspective"><i class="fa fa-check"></i><b>11.1.2</b> Translational research for drug development : Historical perspective</a></li>
</ul></li>
<li class="chapter" data-level="11.2" data-path="MFDS.html"><a href="MFDS.html#session-2-global-regulatory-experiences-in-orphan-drug-development"><i class="fa fa-check"></i><b>11.2</b> Session 2 Global regulatory experiences in orphan drug development</a><ul>
<li class="chapter" data-level="11.2.1" data-path="MFDS.html"><a href="MFDS.html#considerations-for-drug-development-for-rare-diseases-cases-of-inborn-errors-of-metabolism"><i class="fa fa-check"></i><b>11.2.1</b> Considerations for drug development for rare diseases : Cases of inborn errors of metabolism</a></li>
<li class="chapter" data-level="11.2.2" data-path="MFDS.html"><a href="MFDS.html#role-of-pharmacometrics-in-the-development-of-orphan-drugs"><i class="fa fa-check"></i><b>11.2.2</b> Role of pharmacometrics in the development of orphan drugs</a></li>
</ul></li>
<li class="chapter" data-level="11.3" data-path="MFDS.html"><a href="MFDS.html#session-3-lessons-and-learned-rd-for-rare-disease"><i class="fa fa-check"></i><b>11.3</b> Session 3 Lessons and learned : R&amp;D for rare disease</a><ul>
<li class="chapter" data-level="11.3.1" data-path="MFDS.html"><a href="MFDS.html#lessons-from-an-orphan-drug-development-i"><i class="fa fa-check"></i><b>11.3.1</b> Lessons from an orphan drug development (I)</a></li>
<li class="chapter" data-level="11.3.2" data-path="MFDS.html"><a href="MFDS.html#lessons-from-an-orphan-drug-development-ii"><i class="fa fa-check"></i><b>11.3.2</b> Lessons from an orphan drug development (II)</a></li>
<li class="chapter" data-level="11.3.3" data-path="MFDS.html"><a href="MFDS.html#case-studies-on-inflammatory-bowel-disease-asan-medical-center"><i class="fa fa-check"></i><b>11.3.3</b> Case studies on inflammatory bowel disease Asan Medical Center</a></li>
<li class="chapter" data-level="11.3.4" data-path="MFDS.html"><a href="MFDS.html#case-studies-on-drug-targets-in-rare-ultra-rare-genetic-disorders"><i class="fa fa-check"></i><b>11.3.4</b> Case studies on drug targets in rare &amp; ultra-rare genetic disorders</a></li>
</ul></li>
<li class="chapter" data-level="11.4" data-path="MFDS.html"><a href="MFDS.html#session-4-asan-initia-tives-for-rare-disease"><i class="fa fa-check"></i><b>11.4</b> Session 4 Asan initia tives for rare disease</a><ul>
<li class="chapter" data-level="11.4.1" data-path="MFDS.html"><a href="MFDS.html#leverage-big-data-to-better-understand-rare-disease-states-and-patient-needs-rare-disease-registry-research-experience"><i class="fa fa-check"></i><b>11.4.1</b> Leverage big data to better understand rare disease states and patient needs (rare disease registry &amp; research experience)</a></li>
<li class="chapter" data-level="11.4.2" data-path="MFDS.html"><a href="MFDS.html#align-commercial-and-development-team-to-forecast-success-through-prism"><i class="fa fa-check"></i><b>11.4.2</b> Align commercial and development team to forecast success through “PRISM”</a></li>
<li class="chapter" data-level="11.4.3" data-path="MFDS.html"><a href="MFDS.html#knowledge-and-perceptions-of-clinical-research-of-patients-suffering-from-rare-diseases"><i class="fa fa-check"></i><b>11.4.3</b> Knowledge and perceptions of clinical research of patients suffering from rare diseases</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="12" data-path="toxicology-2016.html"><a href="toxicology-2016.html"><i class="fa fa-check"></i><b>12</b> Toxicology 2016</a><ul>
<li class="chapter" data-level="12.1" data-path="toxicology-2016.html"><a href="toxicology-2016.html#key-links"><i class="fa fa-check"></i><b>12.1</b> Key links</a></li>
<li class="chapter" data-level="12.2" data-path="toxicology-2016.html"><a href="toxicology-2016.html#session-i-2016-08-22"><i class="fa fa-check"></i><b>12.2</b> Session I 2016-08-22</a><ul>
<li class="chapter" data-level="12.2.1" data-path="toxicology-2016.html"><a href="toxicology-2016.html#---"><i class="fa fa-check"></i><b>12.2.1</b> 독성학 개론 및 발현기전 !!!!</a></li>
<li class="chapter" data-level="12.2.2" data-path="toxicology-2016.html"><a href="toxicology-2016.html#section-12.2.2"><i class="fa fa-check"></i><b>12.2.2</b> 면역독성 !</a></li>
<li class="chapter" data-level="12.2.3" data-path="toxicology-2016.html"><a href="toxicology-2016.html#-"><i class="fa fa-check"></i><b>12.2.3</b> 독성시험과 통계 !!</a></li>
<li class="chapter" data-level="12.2.4" data-path="toxicology-2016.html"><a href="toxicology-2016.html#section-12.2.4"><i class="fa fa-check"></i><b>12.2.4</b> 독성병리 !!</a></li>
<li class="chapter" data-level="12.2.5" data-path="toxicology-2016.html"><a href="toxicology-2016.html#--"><i class="fa fa-check"></i><b>12.2.5</b> 비임상시험결과의 임상시험 연계 !!!!</a></li>
</ul></li>
<li class="chapter" data-level="12.3" data-path="toxicology-2016.html"><a href="toxicology-2016.html#session-ii-2016-08-23"><i class="fa fa-check"></i><b>12.3</b> Session II 2016-08-23</a><ul>
<li class="chapter" data-level="12.3.1" data-path="toxicology-2016.html"><a href="toxicology-2016.html#---"><i class="fa fa-check"></i><b>12.3.1</b> 오믹스 기반을 이용한 독성평가 !</a></li>
<li class="chapter" data-level="12.3.2" data-path="toxicology-2016.html"><a href="toxicology-2016.html#--"><i class="fa fa-check"></i><b>12.3.2</b> 독성동태 및 대사 !!!</a></li>
<li class="chapter" data-level="12.3.3" data-path="toxicology-2016.html"><a href="toxicology-2016.html#--"><i class="fa fa-check"></i><b>12.3.3</b> 유전독성 및 발암성 !!</a></li>
<li class="chapter" data-level="12.3.4" data-path="toxicology-2016.html"><a href="toxicology-2016.html#section-12.3.4"><i class="fa fa-check"></i><b>12.3.4</b> 신경독성 !</a></li>
<li class="chapter" data-level="12.3.5" data-path="toxicology-2016.html"><a href="toxicology-2016.html#--"><i class="fa fa-check"></i><b>12.3.5</b> 식품의 위해도 평가 !</a></li>
<li class="chapter" data-level="12.3.6" data-path="toxicology-2016.html"><a href="toxicology-2016.html#section-12.3.6"><i class="fa fa-check"></i><b>12.3.6</b> 생식발생독성 !</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="13" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><i class="fa fa-check"></i><b>13</b> 2016년 신약임상개발 전문가 과정 “Clinical Research Science Expert Course for Cutting-edge Drug Development”</a><ul>
<li class="chapter" data-level="13.1" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html#drug-discovery-and-preclinical-candidate-selection"><i class="fa fa-check"></i><b>13.1</b> Drug discovery and preclinical candidate selection</a><ul>
<li class="chapter" data-level="13.1.1" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html#-1st"><i class="fa fa-check"></i><b>13.1.1</b> 김재은 (1ST)</a></li>
</ul></li>
<li class="chapter" data-level="13.2" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html#preclinical-development-and-ind-gono-go-decision-using-case-studies"><i class="fa fa-check"></i><b>13.2</b> Preclinical development and IND go/no-go decision (using case studies)</a></li>
<li class="chapter" data-level="13.3" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html#global-drug-development-and-interaction-with-regulatory-agencies-fda-emea-using-case-studies"><i class="fa fa-check"></i><b>13.3</b> Global drug development and interaction with regulatory agencies (FDA, EMEA) (using case studies)</a></li>
<li class="chapter" data-level="13.4" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html#clinical-pharmacology"><i class="fa fa-check"></i><b>13.4</b> Clinical Pharmacology</a></li>
<li class="chapter" data-level="13.5" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html#the-actual-development-and-operation-of-pharmacovigillance-system-in-korean-pharmaceutical-companies"><i class="fa fa-check"></i><b>13.5</b> The actual development and operation of Pharmacovigillance system in Korean pharmaceutical companies</a><ul>
<li class="chapter" data-level="13.5.1" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html#experience-of-sop-development-pv-training-sharing-pv-audit-finding"><i class="fa fa-check"></i><b>13.5.1</b> Experience of SOP development &amp; PV training/ Sharing PV audit finding</a></li>
<li class="chapter" data-level="13.5.2" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html#establishment-and-application-of-safety-database-system"><i class="fa fa-check"></i><b>13.5.2</b> Establishment and Application of Safety Database System:</a></li>
</ul></li>
<li class="chapter" data-level="13.6" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html#open-innovation-in-drug-development"><i class="fa fa-check"></i><b>13.6</b> Open innovation in drug development</a></li>
<li class="chapter" data-level="13.7" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html#clinical-development-strategy-and-plan-workshop"><i class="fa fa-check"></i><b>13.7</b> Clinical development strategy and plan workshop</a><ul>
<li class="chapter" data-level="13.7.1" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html#course-intro---understanding-tpp-and-hcv"><i class="fa fa-check"></i><b>13.7.1</b> Course intro - Understanding TPP and HCV</a></li>
<li class="chapter" data-level="13.7.2" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html#candidate-selection-through-poc"><i class="fa fa-check"></i><b>13.7.2</b> Candidate selection through PoC</a></li>
<li class="chapter" data-level="13.7.3" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html#late-phase-development-commercialization"><i class="fa fa-check"></i><b>13.7.3</b> Late phase Development &amp; Commercialization</a></li>
<li class="chapter" data-level="13.7.4" data-path="acrep.html"><a href="acrep.html#----"><i class="fa fa-check"></i><b>13.7.4</b> 국내 사례 소개 및 질의/응답</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="14" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html"><i class="fa fa-check"></i><b>14</b> The 2nd A3 Pharmacometrics Symposium</a><ul>
<li class="chapter" data-level="14.1" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html#young-scientist-session"><i class="fa fa-check"></i><b>14.1</b> Young Scientist Session</a><ul>
<li class="chapter" data-level="14.1.1" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html#modeling-of-mycoplasma-tuberculosis-biomarkders-for-cure"><i class="fa fa-check"></i><b>14.1.1</b> Modeling of mycoplasma tuberculosis biomarkders for cure</a></li>
<li class="chapter" data-level="14.1.2" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html#integrative-pkpd-modling-and-simulation-of-amenamevir-for-treatment-of-recurrent-genital-herpes"><i class="fa fa-check"></i><b>14.1.2</b> Integrative PKPD modling and simulation of Amenamevir for treatment of recurrent genital herpes</a></li>
<li class="chapter" data-level="14.1.3" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html#model-based-meta-analysis-to-quantify-and-compare-the-efficacy-of-non-hormonal-drugs-on-menopausal-hot-flashes"><i class="fa fa-check"></i><b>14.1.3</b> Model Based Meta-Analysis to quantify and compare the efficacy of non-hormonal drugs on menopausal Hot flashes</a></li>
<li class="chapter" data-level="14.1.4" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html#dosing-optimization-in-obesity-using-pharmacometrics-approach-population-pk-and-pd-of-meropenem-in-non-obese-obese-and-mobidly-obese-patients"><i class="fa fa-check"></i><b>14.1.4</b> Dosing optimization in obesity using pharmacometrics approach: population PK and PD of meropenem in non-obese, obese and mobidly obese patients</a></li>
</ul></li>
<li class="chapter" data-level="14.2" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html#application-session"><i class="fa fa-check"></i><b>14.2</b> Application Session</a><ul>
<li class="chapter" data-level="14.2.1" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html#the-application-of-pharmacometrics-in-individual-therapy-in-china"><i class="fa fa-check"></i><b>14.2.1</b> The application of pharmacometrics in individual therapy in China</a></li>
<li class="chapter" data-level="14.2.2" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html#pd-model-fo-bayesian-prediction-of-myelosuppression-rpofiles-based-on-routine-clinical-data-after-gemcitabine-and-carboplatin-treatment"><i class="fa fa-check"></i><b>14.2.2</b> PD model fo Bayesian Prediction of myelosuppression rpofiles based on routine clinical data after gemcitabine and carboplatin treatment</a></li>
<li class="chapter" data-level="14.2.3" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html#modeling-and-validating-chronic-pharmacological-manupulation-of-circadian-rhythms"><i class="fa fa-check"></i><b>14.2.3</b> Modeling and validating chronic pharmacological manupulation of circadian rhythms</a></li>
<li class="chapter" data-level="14.2.4" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html#application-of-pkpd-modeling-and-simulation-in-antiviral-drug-development"><i class="fa fa-check"></i><b>14.2.4</b> Application of PK/PD modeling and simulation in antiviral drug development</a></li>
<li class="chapter" data-level="14.2.5" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html#pharmacometrics-in-clinical-practice-pop-pk-analysis-of-febuxostat-in-patients-with-severe-renal-impairment"><i class="fa fa-check"></i><b>14.2.5</b> pharmacometrics in clinical practice: pop PK analysis of febuxostat in patients with severe renal impairment</a></li>
</ul></li>
<li class="chapter" data-level="14.3" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html#regulation"><i class="fa fa-check"></i><b>14.3</b> Regulation</a><ul>
<li class="chapter" data-level="14.3.1" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html#the-new-japanese-guideline-on-population-pk-and-pd-analysis"><i class="fa fa-check"></i><b>14.3.1</b> The new Japanese guideline on population PK and PD analysis</a></li>
<li class="chapter" data-level="14.3.2" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html#how-to-increase-the-number-of-population-pk-analysis-reports-submitted-to-mfds-in-korea"><i class="fa fa-check"></i><b>14.3.2</b> How to increase the number of population PK analysis reports submitted to MFDS in Korea</a></li>
<li class="chapter" data-level="14.3.3" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html#ema-regulations-on-meling-issues"><i class="fa fa-check"></i><b>14.3.3</b> EMA regulations on meling issues</a></li>
<li class="chapter" data-level="14.3.4" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html#recent-examples-of-impact-of-pharmacometrics-in-decision-making"><i class="fa fa-check"></i><b>14.3.4</b> Recent examples of impact of pharmacometrics in decision making</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="15" data-path="asrm-2016.html"><a href="asrm-2016.html"><i class="fa fa-check"></i><b>15</b> ASRM 2016</a><ul>
<li class="chapter" data-level="15.1" data-path="asrm-2016.html"><a href="asrm-2016.html#plenary-lectures"><i class="fa fa-check"></i><b>15.1</b> Plenary lectures</a><ul>
<li class="chapter" data-level="15.1.1" data-path="asrm-2016.html"><a href="asrm-2016.html#plenary-2"><i class="fa fa-check"></i><b>15.1.1</b> Plenary 2</a></li>
<li class="chapter" data-level="15.1.2" data-path="asrm-2016.html"><a href="asrm-2016.html#plenary-lecture-3-the-importance-of-long-acting-reversible-contraception-larc"><i class="fa fa-check"></i><b>15.1.2</b> Plenary Lecture 3 : The importance of Long-acting reversible contraception (LARC)</a></li>
<li class="chapter" data-level="15.1.3" data-path="asrm-2016.html"><a href="asrm-2016.html#plenary-4"><i class="fa fa-check"></i><b>15.1.3</b> Plenary 4</a></li>
<li class="chapter" data-level="15.1.4" data-path="asrm-2016.html"><a href="asrm-2016.html#plenary-5"><i class="fa fa-check"></i><b>15.1.4</b> Plenary 5</a></li>
<li class="chapter" data-level="15.1.5" data-path="asrm-2016.html"><a href="asrm-2016.html#plenary-6-update-on-congenital-adrenal-hyperplasia"><i class="fa fa-check"></i><b>15.1.5</b> Plenary 6 Update on Congenital Adrenal Hyperplasia</a></li>
<li class="chapter" data-level="15.1.6" data-path="asrm-2016.html"><a href="asrm-2016.html#plenary-7---why-parents-matter-epigenetically-genomic-imprinting-in-health-and-disease"><i class="fa fa-check"></i><b>15.1.6</b> Plenary 7 - Why Parents Matter (Epigenetically): Genomic Imprinting in Health and Disease</a></li>
<li class="chapter" data-level="15.1.7" data-path="asrm-2016.html"><a href="asrm-2016.html#plenary-8-aua-bruce-stewart-memorial-lecture-the-futures-of-malereproductive-medicine"><i class="fa fa-check"></i><b>15.1.7</b> Plenary 8: AUA Bruce Stewart Memorial Lecture: The Futures of (Male(Reproductive)) Medicine</a></li>
</ul></li>
<li class="chapter" data-level="15.2" data-path="asrm-2016.html"><a href="asrm-2016.html#prize-oral"><i class="fa fa-check"></i><b>15.2</b> Prize Oral</a><ul>
<li class="chapter" data-level="15.2.1" data-path="asrm-2016.html"><a href="asrm-2016.html#mtor-inhibitors-preserve-fertility-in-a-murine-model-a-novel-pharmacologic-approach-to-fertility-preservation-during-gonadotoxic-chemotherapy"><i class="fa fa-check"></i><b>15.2.1</b> mTOR inhibitors preserve fertility in a murine model : a novel pharmacologic approach to fertility preservation during gonadotoxic chemotherapy</a></li>
<li class="chapter" data-level="15.2.2" data-path="asrm-2016.html"><a href="asrm-2016.html#verification-of-accuracy-safety-for-ovarian-reserve-assessment-with-optical-coherence-tomography-using-mouse-ovary"><i class="fa fa-check"></i><b>15.2.2</b> Verification of accuracy &amp; safety for ovarian reserve assessment with optical coherence tomography using mouse ovary</a></li>
<li class="chapter" data-level="15.2.3" data-path="asrm-2016.html"><a href="asrm-2016.html#o-6-randomized-controlled-trial-of-low-5-vs.-ultralow-2-oxygen-tension-for-in-vitro-development-of-human-embryos"><i class="fa fa-check"></i><b>15.2.3</b> O-6 RANDOMIZED CONTROLLED TRIAL OF LOW (5%) VS. ULTRALOW (2%) OXYGEN TENSION FOR IN VITRO DEVELOPMENT OF HUMAN EMBRYOS</a></li>
</ul></li>
<li class="chapter" data-level="15.3" data-path="asrm-2016.html"><a href="asrm-2016.html#symposium-overview-of-food-and-drug-administration-fda-regulations-of-products-used-to-treat-reproductive-conditions-in-women"><i class="fa fa-check"></i><b>15.3</b> Symposium : Overview of Food and Drug Administration (FDA) Regulations of Products Used to Treat Reproductive Conditions in Women</a><ul>
<li class="chapter" data-level="15.3.1" data-path="asrm-2016.html"><a href="asrm-2016.html#richard-d.-mcfarland-m.d.-ph.d."><i class="fa fa-check"></i><b>15.3.1</b> Richard D. McFarland, M.D., Ph.D.</a></li>
<li class="chapter" data-level="15.3.2" data-path="asrm-2016.html"><a href="asrm-2016.html#rhonda---cder-drug-review-process"><i class="fa fa-check"></i><b>15.3.2</b> Rhonda - CDER Drug review process</a></li>
<li class="chapter" data-level="15.3.3" data-path="asrm-2016.html"><a href="asrm-2016.html#cdrh-center-for-devices-and-radiological-health"><i class="fa fa-check"></i><b>15.3.3</b> CDRH (Center for Devices and Radiological Health)</a></li>
<li class="chapter" data-level="15.3.4" data-path="asrm-2016.html"><a href="asrm-2016.html#endometriosis-tuesday-expo-theater"><i class="fa fa-check"></i><b>15.3.4</b> Endometriosis, Tuesday EXPO theater</a></li>
</ul></li>
<li class="chapter" data-level="15.4" data-path="asrm-2016.html"><a href="asrm-2016.html#scientific-congress-prize-paper-session-2"><i class="fa fa-check"></i><b>15.4</b> Scientific Congress Prize Paper Session 2</a><ul>
<li class="chapter" data-level="15.4.1" data-path="asrm-2016.html"><a href="asrm-2016.html#o-91-preovulatory-protein-restriction-ppr-disrupted-amino-acid-aa-kinetics-and-mitochondrial-structure-and-function-in-the-rat-oocyte"><i class="fa fa-check"></i><b>15.4.1</b> O-91 PREOVULATORY PROTEIN RESTRICTION (PPR): DISRUPTED AMINO ACID (AA) KINETICS AND MITOCHONDRIAL STRUCTURE AND FUNCTION IN THE RAT OOCYTE</a></li>
<li class="chapter" data-level="15.4.2" data-path="asrm-2016.html"><a href="asrm-2016.html#o-92-effects-of-resveratrol-on-polycystic-ovary-syndrome"><i class="fa fa-check"></i><b>15.4.2</b> O-92 EFFECTS OF RESVERATROL ON POLYCYSTIC OVARY SYNDROME</a></li>
<li class="chapter" data-level="15.4.3" data-path="asrm-2016.html"><a href="asrm-2016.html#o-93-genome-wide-dna-methylation-changes-in-mouse-zygotes-associated-with-superovulation"><i class="fa fa-check"></i><b>15.4.3</b> O-93 GENOME-WIDE DNA METHYLATION CHANGES IN MOUSE ZYGOTES ASSOCIATED WITH SUPEROVULATION</a></li>
<li class="chapter" data-level="15.4.4" data-path="asrm-2016.html"><a href="asrm-2016.html#o-94-can-we-expect-to-improve-age-at-menopause-predictions-with-repeated-amh-measurements"><i class="fa fa-check"></i><b>15.4.4</b> O-94 CAN WE EXPECT TO IMPROVE AGE AT MENOPAUSE PREDICTIONS WITH REPEATED AMH MEASUREMENTS?</a></li>
</ul></li>
<li class="chapter" data-level="15.5" data-path="asrm-2016.html"><a href="asrm-2016.html#oral-presentation"><i class="fa fa-check"></i><b>15.5</b> Oral Presentation</a><ul>
<li class="chapter" data-level="15.5.1" data-path="asrm-2016.html"><a href="asrm-2016.html#o-229-the-impact-of-elagolix-on-quality-of-life-in-women-with-endometriosis-associated-pain-results-from-two-randomized-placebo-controlled-studies-using-the-endometriosis-health-profile-questionnaire-hugh-taylor"><i class="fa fa-check"></i><b>15.5.1</b> O-229 THE IMPACT OF ELAGOLIX ON QUALITY OF LIFE IN WOMEN WITH ENDOMETRIOSIS-ASSOCIATED PAIN: RESULTS FROM TWO RANDOMIZED, PLACEBO-CONTROLLED STUDIES USING THE ENDOMETRIOSIS HEALTH PROFILE QUESTIONNAIRE (Hugh Taylor)</a></li>
<li class="chapter" data-level="15.5.2" data-path="asrm-2016.html"><a href="asrm-2016.html#o-230-direct-and-indirect-costs-associated-with-endometriosis-related-surgery-among-employed-women-in-the-us"><i class="fa fa-check"></i><b>15.5.2</b> O-230 DIRECT AND INDIRECT COSTS ASSOCIATED WITH ENDOMETRIOSIS-RELATED SURGERY AMONG EMPLOYED WOMEN IN THE US</a></li>
<li class="chapter" data-level="15.5.3" data-path="asrm-2016.html"><a href="asrm-2016.html#o-231-new-procedure-for-the-endometriosis-diagnosis"><i class="fa fa-check"></i><b>15.5.3</b> O-231 NEW PROCEDURE FOR THE ENDOMETRIOSIS DIAGNOSIS</a></li>
<li class="chapter" data-level="15.5.4" data-path="asrm-2016.html"><a href="asrm-2016.html#o-232-elagolix-on-endometrium"><i class="fa fa-check"></i><b>15.5.4</b> O-232 Elagolix on endometrium</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="16" data-path="kscpt-2016-fall.html"><a href="kscpt-2016-fall.html"><i class="fa fa-check"></i><b>16</b> KSCPT 2016 Fall</a><ul>
<li class="chapter" data-level="16.1" data-path="kscpt-2016-fall.html"><a href="kscpt-2016-fall.html#therapeutics-new-target"><i class="fa fa-check"></i><b>16.1</b> Therapeutics : New target</a><ul>
<li class="chapter" data-level="16.1.1" data-path="kscpt-2016-fall.html"><a href="kscpt-2016-fall.html#a-new-target-for-hiv-1-aids-drug"><i class="fa fa-check"></i><b>16.1.1</b> A new target for HIV-1 / AIDS drug</a></li>
<li class="chapter" data-level="16.1.2" data-path="kscpt-2016-fall.html"><a href="kscpt-2016-fall.html#new-drug-target-for-osteoporosis-gpr120"><i class="fa fa-check"></i><b>16.1.2</b> New drug target for osteoporosis: GPR120</a></li>
<li class="chapter" data-level="16.1.3" data-path="kscpt-2016-fall.html"><a href="kscpt-2016-fall.html#strategy-for-anti-cancer-target"><i class="fa fa-check"></i><b>16.1.3</b> Strategy for Anti-Cancer Target</a></li>
<li class="chapter" data-level="16.1.4" data-path="toxicology-2016.html"><a href="toxicology-2016.html#--"><i class="fa fa-check"></i><b>16.1.4</b> 재발자궁경부암 항암화학방사선 온열동시치료</a></li>
</ul></li>
<li class="chapter" data-level="16.2" data-path="kscpt-2016-fall.html"><a href="kscpt-2016-fall.html#drug-development-i"><i class="fa fa-check"></i><b>16.2</b> Drug development I</a><ul>
<li class="chapter" data-level="16.2.1" data-path="kscpt-2016-fall.html"><a href="kscpt-2016-fall.html#non-clinical-considerations-for-fih"><i class="fa fa-check"></i><b>16.2.1</b> Non-clinical considerations for FIH</a></li>
<li class="chapter" data-level="16.2.2" data-path="kscpt-2016-fall.html"><a href="kscpt-2016-fall.html#------"><i class="fa fa-check"></i><b>16.2.2</b> 임상약리학 주도 환자 대상 초기임상시험의 경험과 전망</a></li>
<li class="chapter" data-level="16.2.3" data-path="kscpt-2016-fall.html"><a href="kscpt-2016-fall.html#the-contribution-of-clinical-pharmacologist-in-global-drug-development-real-examples-from-a-big-pharma"><i class="fa fa-check"></i><b>16.2.3</b> The Contribution of Clinical Pharmacologist in Global Drug Development: Real Examples from a Big Pharma</a></li>
</ul></li>
<li class="chapter" data-level="16.3" data-path="kscpt-2016-fall.html"><a href="kscpt-2016-fall.html#drug-development-ii--"><i class="fa fa-check"></i><b>16.3</b> Drug development II 신상구 (차바이오컴플렉스)</a><ul>
<li class="chapter" data-level="16.3.1" data-path="kscpt-2016-fall.html"><a href="kscpt-2016-fall.html#babe------vs-"><i class="fa fa-check"></i><b>16.3.1</b> BA/BE 임상시험 결과분석 시 고려사항: 분산투여 vs 추가시험</a></li>
<li class="chapter" data-level="16.3.2" data-path="kscpt-2016-fall.html"><a href="kscpt-2016-fall.html#the-use-of-pharmacometrics-for-drug-development-in-korea"><i class="fa fa-check"></i><b>16.3.2</b> The use of pharmacometrics for drug development in Korea</a></li>
<li class="chapter" data-level="16.3.3" data-path="kscpt-2016-fall.html"><a href="kscpt-2016-fall.html#fatal-bia-10-2474-phase-i-clinical-trial-what-can-we-learn"><i class="fa fa-check"></i><b>16.3.3</b> Fatal BIA 10-2474 Phase I Clinical Trial : What Can We Learn?</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="17" data-path="will-big-data-and-data-science-reshape-the-horizon-of-drug-development-if-so-how.html"><a href="will-big-data-and-data-science-reshape-the-horizon-of-drug-development-if-so-how.html"><i class="fa fa-check"></i><b>17</b> 2016-11-18 Will big data and data science reshape the horizon of drug development?, If so, how?</a><ul>
<li class="chapter" data-level="17.1" data-path="will-big-data-and-data-science-reshape-the-horizon-of-drug-development-if-so-how.html"><a href="will-big-data-and-data-science-reshape-the-horizon-of-drug-development-if-so-how.html#jscpt"><i class="fa fa-check"></i><b>17.1</b> JSCPT</a><ul>
<li class="chapter" data-level="17.1.1" data-path="will-big-data-and-data-science-reshape-the-horizon-of-drug-development-if-so-how.html"><a href="will-big-data-and-data-science-reshape-the-horizon-of-drug-development-if-so-how.html#--------"><i class="fa fa-check"></i><b>17.1.1</b> 대규모 약물 유도 전사체 정보 기반 항암 신약 재창출</a></li>
<li class="chapter" data-level="17.1.2" data-path="will-big-data-and-data-science-reshape-the-horizon-of-drug-development-if-so-how.html"><a href="will-big-data-and-data-science-reshape-the-horizon-of-drug-development-if-so-how.html#big-data-platform-for-multi-national-data-collaboration"><i class="fa fa-check"></i><b>17.1.2</b> Big data platform for multi-national data collaboration</a></li>
<li class="chapter" data-level="17.1.3" data-path="will-big-data-and-data-science-reshape-the-horizon-of-drug-development-if-so-how.html"><a href="will-big-data-and-data-science-reshape-the-horizon-of-drug-development-if-so-how.html#yoshinori-ochiai-pharmaceuticals-and-medical-devices-agency"><i class="fa fa-check"></i><b>17.1.3</b> Yoshinori Ochiai (Pharmaceuticals and Medical Devices Agency)</a></li>
<li class="chapter" data-level="17.1.4" data-path="will-big-data-and-data-science-reshape-the-horizon-of-drug-development-if-so-how.html"><a href="will-big-data-and-data-science-reshape-the-horizon-of-drug-development-if-so-how.html#how-big-data-national-registry-data-can-be-a-game-changer"><i class="fa fa-check"></i><b>17.1.4</b> How big data (national registry data) can be a game changer?</a></li>
</ul></li>
<li class="chapter" data-level="17.2" data-path="will-big-data-and-data-science-reshape-the-horizon-of-drug-development-if-so-how.html"><a href="will-big-data-and-data-science-reshape-the-horizon-of-drug-development-if-so-how.html#how-can-clinical-pharmacology-facilitate-collaboration-between-the-drug-development-industry-and-academia-particularly-in-the-asian-pacific-region"><i class="fa fa-check"></i><b>17.2</b> How can clinical pharmacology facilitate collaboration between the drug development industry and academia, particularly in the Asian-Pacific region?</a><ul>
<li class="chapter" data-level="17.2.1" data-path="will-big-data-and-data-science-reshape-the-horizon-of-drug-development-if-so-how.html"><a href="will-big-data-and-data-science-reshape-the-horizon-of-drug-development-if-so-how.html#thyroid"><i class="fa fa-check"></i><b>17.2.1</b> Thyroid</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="18" data-path="section.html"><a href="section.html"><i class="fa fa-check"></i><b>18</b> 2017-03-20</a></li>
<li class="chapter" data-level="19" data-path="reference.html"><a href="reference.html"><i class="fa fa-check"></i><b>19</b> Reference</a></li>
<li class="divider"></li>
<li><a href="http://shanmdphd.github.io">Back to shanmdphd.github.io</a></li>

</ul>

      </nav>
    </div>

    <div class="book-body">
      <div class="body-inner">
        <div class="book-header" role="navigation">
          <h1>
            <i class="fa fa-circle-o-notch fa-spin"></i><a href="./">Summary of Conferences 2016</a>
          </h1>
        </div>

        <div class="page-wrapper" tabindex="-1" role="main">
          <div class="page-inner">

            <section class="normal" id="section-">
<div id="----clinical-research-science-expert-course-for-cutting-edge-drug-development" class="section level1">
<h1><span class="header-section-number">Chapter 13</span> 2016년 신약임상개발 전문가 과정 “Clinical Research Science Expert Course for Cutting-edge Drug Development”</h1>
<ul>
<li>교육기간 : 2016. 09. 29(목) ~ 2016. 09. 30(금) (2일)</li>
<li>교육시간 : 9:00~18:00</li>
<li>교육장소 : 서울대학교병원 암병원, 서성환홀</li>
</ul>
<div id="drug-discovery-and-preclinical-candidate-selection" class="section level2">
<h2><span class="header-section-number">13.1</span> Drug discovery and preclinical candidate selection</h2>
<ul>
<li>Be knowledgeable to project initiation processes for drug discovery as the first step</li>
<li>Be familiar with how to identify and validate drug targets with given indication and pathology</li>
<li>Understand each step in usual drug discovery paths mainly in the field of disease biology, assay development, high-throughput screening, medicinal chemistry, and early DMPK</li>
<li>Identify major milestones including hit generation, hit-to-lead, and lead-to-candidate processes and their evaluation factors to make go/no go decision entering into preclinical development accordingly</li>
<li>Exemplify several cases in actual drug discovery projects with success or failure and assess the main factors affecting success rate</li>
</ul>
<div id="-1st" class="section level3">
<h3><span class="header-section-number">13.1.1</span> 김재은 (1ST)</h3>
<ul>
<li><strong>Discovery</strong></li>
<li>E-room’s law (1b 사용해서 나오는 약의 개수는 해마다 감소하고 있다.)</li>
<li>Overall discovery process</li>
<li>Objectives of discovery
<ul>
<li>가장 중요한건 <strong>patentable</strong></li>
<li>Potently and specifically recognizes target</li>
<li>Nice metabolism and PK characteristics</li>
</ul></li>
<li>Target 선정.</li>
<li>Lead to Candidate</li>
<li>Biologics:
<ul>
<li>growing sales</li>
<li>NCE, 생체유래 biologics</li>
<li>Oligonuc. - biologics인가? 너무 길어서 CHO Cell에서 생산해야 한다-biologics로 분류</li>
<li>mAb가 가장 많습니다. 그 다음 vaccine입니다.</li>
<li>Fab만 갖는 것도 만들기도 함.</li>
</ul></li>
<li>bispecific
<ul>
<li>2 Arms</li>
<li>BiTE (T cell engaging) - CD3, CD19</li>
</ul></li>
<li>ADC
<ul>
<li>Antibody Drug Conjugate</li>
<li>Herceptin + DM1 toxin</li>
</ul></li>
<li>Immuno-oncology
<ul>
<li>약이 네개 나와있다.</li>
<li>anti-PD-1, anti-CTLA-4<br />
</li>
<li>Seal breaker (Checkpoint inhibitor) + activation 유지해 주는 역할(activating receptor)</li>
<li>restoring immunity</li>
<li>T cell receptor + MHC</li>
</ul></li>
<li>CAR-T
<ul>
<li>scFv - tumor cell targeting</li>
<li>Co-stim 1, Co-stim 2 -&gt; T cell (Signal 1 and 2)</li>
</ul></li>
<li><ol start="17" style="list-style-type: upper-alpha">
<li>Pubmed에 나와있지 않은 경우는 어떻게?</li>
</ol>
<ul>
<li><ol style="list-style-type: upper-alpha">
<li>Target validation해야 한다. (functional study)</li>
</ol></li>
</ul></li>
<li><ol start="17" style="list-style-type: upper-alpha">
<li>Library의 target성격?</li>
</ol>
<ul>
<li><ol style="list-style-type: upper-alpha">
<li>10^6개의 Chemical diversity, human Ab library도 있다.</li>
</ol></li>
</ul></li>
</ul>
</div>
</div>
<div id="preclinical-development-and-ind-gono-go-decision-using-case-studies" class="section level2">
<h2><span class="header-section-number">13.2</span> Preclinical development and IND go/no-go decision (using case studies)</h2>
<ul>
<li>Speaker: 이성숙(NOV)</li>
</ul>
</div>
<div id="global-drug-development-and-interaction-with-regulatory-agencies-fda-emea-using-case-studies" class="section level2">
<h2><span class="header-section-number">13.3</span> Global drug development and interaction with regulatory agencies (FDA, EMEA) (using case studies)</h2>
<ul>
<li>Speaker: 이형기(서울의대), 김한주(유한), 이장익(서울약대)</li>
<li>Open question이 아닌 closed question해야 한다.</li>
<li>F2F에서는 Listen해야하고 끝나고 debrief하는 과정이 반드시 필요하다.</li>
</ul>
</div>
<div id="clinical-pharmacology" class="section level2">
<h2><span class="header-section-number">13.4</span> Clinical Pharmacology</h2>
<ul>
<li>Speaker: 최성준(보령), 신동훈(삼성)</li>
</ul>
</div>
<div id="the-actual-development-and-operation-of-pharmacovigillance-system-in-korean-pharmaceutical-companies" class="section level2">
<h2><span class="header-section-number">13.5</span> The actual development and operation of Pharmacovigillance system in Korean pharmaceutical companies</h2>
<div id="experience-of-sop-development-pv-training-sharing-pv-audit-finding" class="section level3">
<h3><span class="header-section-number">13.5.1</span> Experience of SOP development &amp; PV training/ Sharing PV audit finding</h3>
<ul>
<li>speaker: 김수원 (동아)</li>
<li>“제약현장에서의 약물감시체계”</li>
<li>27개의 신약이 나왔습니다. 현재까지</li>
<li>PV개념이 없을때 부터 도입이 되었다. 어려움이 있었다. PMS부서에서 audit 받았다.</li>
<li>Partner company로 부터 여러가지 이슈에 대한 지적을 받음.
<ul>
<li>Audit findings (2012)
<ul>
<li>Lack of reconciliation process</li>
<li>Deficiencies in Local literature search</li>
</ul></li>
<li>Due deligence (2013)
<ul>
<li>Not enough staff dedicated to PV</li>
<li>Lack of Global PV DB</li>
</ul></li>
<li>이런 분야를 만들어야겠다는 사장단의 의지가 있었습니다.</li>
</ul></li>
<li>Work scope of PV</li>
</ul>
</div>
<div id="establishment-and-application-of-safety-database-system" class="section level3">
<h3><span class="header-section-number">13.5.2</span> Establishment and Application of Safety Database System:</h3>
<ul>
<li>백은아(보령)</li>
<li>DB 구축</li>
<li>매핑</li>
<li><ol start="17" style="list-style-type: upper-alpha">
<li>연구자에게 필요한 것은?(부산대 최상민 교수님)</li>
</ol>
<ul>
<li><ol style="list-style-type: upper-alpha">
<li>10일 안에 뿌려줘야 한다. DCF보내야 하는데 속도 문제. 10일. 충실도가 높아야 한다.</li>
</ol></li>
</ul></li>
</ul>
</div>
</div>
<div id="open-innovation-in-drug-development" class="section level2">
<h2><span class="header-section-number">13.6</span> Open innovation in drug development</h2>
<ul>
<li>Speaker: 김한주, 남수연(유한)</li>
<li>SGLT2 - 심혈관계 위험 낮춤</li>
<li>당뇨신약 CV risk assessment 필요하다</li>
<li>Efficacy 안나오는 경우는 human dose selection 잘 안되는 경우가 많다.</li>
<li>Druggability - PK나와야 한다(QD면 QD에 맞게)</li>
<li>Open innovation의 방향이 변한다.</li>
<li>기술을 사올때 - Target이 얼마나 novel한지? Platform technology인 경우는 feasible한지의 검토를 많이 한다. Strong science, Quality of Data</li>
<li>가장 중요하다. Communication, Team Work, Value Share</li>
<li>Assets &amp; IP Review, Agreement on TPP, Valuation, In-licensing &amp; investment, Value Creation &amp; Profit Sharing</li>
<li>물건 사가서 아무것도 안하는 경우 많다. Clear path를 보여줘야 신뢰가 쌓인다.</li>
<li>Feasibility test</li>
<li>Science를 할때는 science가 중심이 되어야 한다</li>
<li>소렌토와 Joint Venture Company - 다음에 이야기 합시다. 항체 라이브러리를 갖고 있는 미국회사. ImmuneOncia - 10million(Yuhan) + 3 assets(미국회사, San Diego) - 개발비로 PD-1, PD-L1을 사용해서 add-on therapy에 대한 임상시험을 할 수 있다.</li>
<li>PD-L1 kit $150000 우리나라에서 1억2천</li>
<li>YH25448 Case I : 사는 이야기
<ul>
<li>AZD, CO(Clovis), HM</li>
<li>Sparing EGFR wildtype</li>
<li>Brain Mets</li>
<li>항암신약산업단 - TPP를 준비했다. brain mets.</li>
<li>3세대는 Wild type 안건들고 selectivity가 좋더라.</li>
<li>DMPK studies, PK-PD modeling 등 pitching했다.</li>
<li>7/30에 샀다. (15억)</li>
</ul></li>
<li>YH25448 Case II : 파는 이야기
<ul>
<li>Building up TPP</li>
<li>Intracranial activity</li>
<li>클로비스의 metabolite 독성이 있다.</li>
<li>AZD -</li>
<li>Salt -&gt; Physicochemical property 좋아졌다.</li>
<li>HM - Beringer가 포기한 이유 (ORR 55%) Competitive landscape</li>
<li>T790M EGFR inhibitor</li>
<li>중국에는 폐암환자 많다. Alotinib보다 로컬 약을 많이 쓰고 있었습니다.</li>
<li>중국-뤄신</li>
</ul></li>
<li>“Excellence in Science which translates into substantial Clinical Benefit”</li>
<li><a href="http://www.asiae.co.kr/news/view.htm?idxno=2016072809553938303">유한양행, 중국 뤄신에 비소세포폐암 표적치료제 신약후보물질 기술이전</a></li>
</ul>
</div>
<div id="clinical-development-strategy-and-plan-workshop" class="section level2">
<h2><span class="header-section-number">13.7</span> Clinical development strategy and plan workshop</h2>
<ul>
<li>Understand purpose of clinical development plan and its key components</li>
<li>Evaluate and analyses target indications and identify unmet therapeutic needs</li>
<li>Assess market potential and competition around target indications</li>
<li>Describe product profile with relevant evidence developed for target indications</li>
<li>Create project plan including key milestones and budget</li>
<li>Evaluate and apply regulatory aspects underpinning clinical development</li>
<li>Draft target product profile(TPP) with proposed indications and promotional claims</li>
<li>Identify and assess program risks and develop mitigation strategies</li>
</ul>
<div id="course-intro---understanding-tpp-and-hcv" class="section level3">
<h3><span class="header-section-number">13.7.1</span> Course intro - Understanding TPP and HCV</h3>
<ul>
<li>안종호(MSD)</li>
<li>TPP and HCV</li>
<li>Efficacy, Tolerability, Convenience, Other - TPP</li>
</ul>
</div>
<div id="candidate-selection-through-poc" class="section level3">
<h3><span class="header-section-number">13.7.2</span> Candidate selection through PoC</h3>
<ul>
<li>임경수(차의대), 이승환(서울의대)</li>
<li>1,4형에 대한 medical unmet need 많다.</li>
<li>protease inhibitor, polymerase inhibitor</li>
<li>우리도 Durg X 개발. Protease inhibitor만들자.</li>
<li>비임상시험결과. FIH study를 B병원에서 진행하기로 함.</li>
<li>질문1. FIH연구는 어떠한 목적을 갖고 수행? 우선순위? Endpoint들은 어떤것?</li>
<li>자료1. HED 이 용량 사람에게 줬을때.</li>
<li>FIH
<ul>
<li>Endpoint - Safety/tolerability (적절한 방법으로 적절한 시간에)</li>
<li>Metabolite에 대한 PK</li>
<li>비임상에서 규명되지 않은 metabolite나올 수도 있음.</li>
<li>for early proof-of-concept : surrogate biomarker</li>
<li>ex vivo PD (challenge test) - 연구소와 같이 해볼 수 있다. (탐색적 목적)</li>
<li>항생제 같은 경우 모델이 잘 정립되어 있음. 항바이러스제는 모델이 정립안되어있어.</li>
<li>Hybrid로도 할 수 있다. (일정 용량까지는 자원자로, 최대용량에서 환자 대상으로?)</li>
<li>Parallel vs cross-over</li>
<li>MTD 찾는게 목적이 아니다.</li>
</ul></li>
<li>Go/No-go
<ul>
<li>40mg*2.5배</li>
<li>8.8이상도 유지 (20,40에서도 개발 가능할 것임)</li>
<li>Renal transport - mechanistic problem 연구소에 요청해서 탐색해봐야 함</li>
<li>Affecting factors (Safety, efficacy, PK, marketability)</li>
</ul></li>
</ul>
</div>
<div id="late-phase-development-commercialization" class="section level3">
<h3><span class="header-section-number">13.7.3</span> Late phase Development &amp; Commercialization</h3>
<ul>
<li>이소라(Abbvie), 문준식(SK케미칼)</li>
<li>NDA 제출시에 pivotal phase III 적어도 두개는 해야 합니다.</li>
</ul>
</div>
<div id="----" class="section level3">
<h3><span class="header-section-number">13.7.4</span> 국내 사례 소개 및 질의/응답</h3>
<ul>
<li>손지웅(한미약품)</li>
<li>2010~ 한미</li>
<li>한국은 early phase development 하는 기회가 늘어나고 있습니다.</li>
<li>특히 oncology 측면에서 그러합니다.</li>
<li>Target - Hit - Lead - Lead opt - Pre-nom. -</li>
<li>Early clinical development - Lead optimization 되는 시점부터 시작된다고 봅니다.
<ul>
<li>Animal to human 예측 못하는 영역이 많습니다.</li>
<li>Interaction between investigator, regulartor, and sponsor is important.</li>
</ul></li>
<li>Pneumonia - 예전과 현재</li>
<li>관점의 변화 Cancer - pathology -&gt; genetics</li>
<li>Establish realistic expectation! 기대값을 낮춰야 함.</li>
<li>Strategy to overcome innovation crisis
<ul>
<li><strong>Open Innovation</strong>이 요즘의 화두입니다. 열린 깔데기로 확률을 높이는 것을 목적으로 합니다.</li>
<li>실제로 구현하기 어렵습니다. Virtual operation</li>
<li>Evolution to open innovation : lean and mean organization</li>
<li>Adaptive clinical trial design</li>
</ul></li>
</ul>
<div class="figure">
<img src="http://i.imgur.com/ouxeUJu.png" />

</div>

</div>
</div>
</div>
            </section>

          </div>
        </div>
      </div>
<a href="toxicology-2016.html" class="navigation navigation-prev " aria-label="Previous page"><i class="fa fa-angle-left"></i></a>
<a href="the-2nd-a3-pharmacometrics-symposium.html" class="navigation navigation-next " aria-label="Next page"><i class="fa fa-angle-right"></i></a>
    </div>
  </div>
<script src="libs/gitbook/js/app.min.js"></script>
<script src="libs/gitbook/js/lunr.js"></script>
<script src="libs/gitbook/js/plugin-search.js"></script>
<script src="libs/gitbook/js/plugin-sharing.js"></script>
<script src="libs/gitbook/js/plugin-fontsettings.js"></script>
<script src="libs/gitbook/js/plugin-bookdown.js"></script>
<script src="libs/gitbook/js/jquery.highlight.js"></script>
<script>
require(["gitbook"], function(gitbook) {
gitbook.start({
"sharing": {
"github": false,
"facebook": true,
"twitter": true,
"google": false,
"weibo": false,
"instapper": false,
"vk": false,
"all": ["facebook", "google", "twitter", "weibo", "instapaper"]
},
"fontsettings": {
"theme": "white",
"family": "sans",
"size": 2
},
"edit": {
"link": "https://github.com/shanmdphd/shanmdphd.github.io/edit/master/_ConferencesSource/2016-09-29-New-Drug.Rmd",
"text": "Edit"
},
"download": ["bookdown.pdf", "bookdown.epub", "bookdown.mobi"],
"toc": {
"collapse": "subsection"
}
});
});
</script>

<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://cdn.mathjax.org/mathjax/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    if (location.protocol !== "file:" && /^https?:/.test(script.src))
      script.src  = script.src.replace(/^https?:/, '');
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>
</body>

</html>
